- Open Access
Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study
© Riou et al.; licensee BioMed Central Ltd. 2014
- Received: 13 January 2014
- Accepted: 18 May 2014
- Published: 2 June 2014
To assess the feasibility and benefit of integrating four-dimensional (4D) Positron Emission Tomography (PET) – computed tomography (CT) for liver stereotactic body radiation therapy (SBRT) planning.
8 patients with 14 metastases were accrued in the study. They all underwent a non-gated PET and a 4D PET centered on the liver. The same CT scan was used for attenuation correction, registration, and considered the planning CT for SBRT planning. Six PET phases were reconstructed for each 4D PET. By applying an individualized threshold to the 4D PET, a Biological Internal Target Volume (BITV) was generated for each lesion. A gated Planning Target Volume (PTVg) was created by adding 3 mm to account for set-up margins. This volume was compared to a manual Planning Target Volume (PTV) delineated with the help of a semi-automatic Biological Target Volume (BTV) obtained from the non-gated exam. A 5 mm radial and a 10 mm craniocaudal margins were applied to account for tumor motion and set-up margins to create the PTV.
One undiagnosed liver metastasis was discovered thanks to the 4D PET. The semi-automatic BTV were significantly smaller than the BITV (p = 0.0031). However, after applying adapted margins, 4D PET allowed a statistically significant decrease in the PTVg as compared to the PTV (p = 0.0052).
In comparison to non-gated PET, 4D PET may better define the respiratory movements of liver targets and improve SBRT planning for liver metastases. Furthermore, non respiratory-gated PET exams can both misdiagnose liver metastases and underestimate the real internal target volumes.
- Respiratory-gated PET
- Liver metastases
- Radiotherapy planning
- 4D PET
Although surgery is the standard of care for resectable liver metastases, less invasive local options like radiofrequency ablation and stereotactic body radiation therapy (SBRT) are available with promising results [1–4]. Limitations for radiation use in liver tumors (primaries or metastases) have been two-fold historically, namely limited tumor dose shaping possibilities using tridimensional irradiation due to respiratory motion and liver radiosensitivity leading in rare occasions to lethal radiation-induced liver disease (RILD) [1, 5]. Technological advances in Radiation Oncology have dramatically changed the management of liver tumors, with gating and tracking on one hand and SBRT and intensity modulated radiotherapy (IMRT) techniques on the other, both allowing more conformal irradiation, and reducing RILD to less than 5% [6–8]. Treatment planning for liver radiotherapy is challenging when using computed tomography (CT) scan alone. Contrast medium injection helps to define target volumes but is insufficiently standardized and efficient to reduce inter-individual variability in delineation . Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are helpful to counteract this variability, but fusion uncertainty, mostly due to different respiratory cycle phases, results in unreliable volume definition when planning high precision treatment such as IMRT or SBRT . Irradiation of liver tumors can be proposed to unresectable metastases and hepatocarcinomas, or patients awaiting liver grafts. Unlike for hepatocarcinoma , [18 F]FluoroDeoxyGlucose ([18 F]FDG) PET-CT imaging sensitivity to diagnose liver metastases is rather high .
The use of PET-CT for radiotherapy planning results in a change in target volume definition for most of the cases (84%), with an overall CTV increase of about 25% . By contrast, four-dimensional (4D) PET-CT has been shown to decrease target volumes in lung cancer by as much as 34%, along with a rise in uptake values, which theoretically leads to a better tumor definition . The usefulness of 4D PET-CT for radiotherapy planning has been recently evaluated in lung tumors [15, 16] and for liver radiotherapy planning , but this study represents the first intent to compare a planning method with PET-CT to another incorporating 4D PET.
Liver metastases segmentation description
We investigated the reliability of establishing a personalized threshold segmentation method based on normal liver SUVmax for tumor measurements. We first evaluated this method on phantom studies and then applied the same methodology to patient cases.
This methodology is described below.
The PET reconstruction parameters were as following: 2 iterations, 21 subsets, Gaussian filter (FWHM = 2 mm), 2 mm slice thickness, matrix 512×512, True X (Ordered-Subsets Expectation Maximization algorithm, Point-Spread Function with Time-Of-Flight) (Ultra HD-PET).
Liver metastases segmentation evaluation on phantom
Phantom studies were performed with 150 seconds PET acquisition. The CT scan was used for attenuation correction and registration for PET acquisitions. We used the list mode of a Siemens Biograph mCT to get the six phase of the gated PET. The Siemens Biograph mCT was fitted with four rings and time of flight, corresponding to 32 448 LSO detectors, with each detector dimension being 4 mm × 4 mm × 20 mm. The transaxial field of view (FOV) was 50 cm and the length of the axial direction was 21.6 cm, allowing covering the whole phantom in one step.
The background SUVmax was used as the segmentation threshold to provide the measured volume in each experimental condition. Standardized Uptake Value (SUV) max was worked out for each experimental condition on the liver-like part of the phantom within a 20 to 30 cm3 ROI inside a healthy part of the liver. To have a more reliable value, 3 ROI were used when differences of less than 0.1 in the SUVmax values were obtained. Two additional measurements were added when differences between 0.1 and 0.2 were obtained. No differences higher than 0.2 were obtained.
Patients with liver oligometastases eligible to SBRT treatment were consecutively included in the study.
PET-CT and 4D PET-CT
All patients underwent a standard non-gated PET (150 seconds acquisition per bed position) and a respiratory-gated PET immediately afterwards. For a whole body non-gated PET with a mean of 7 bed positions, the acquisition was 17.5 min. The respiratory-gated PET was done during one bed position and took approximately 10 min.
The same CT scan was used for attenuation correction and registration for both PET acquisitions. CT and PET acquisition were made during uncoached quiet free breathing. PET data were acquired 60 minutes post injection of [18 F]FDG, using the list mode of a Siemens CT fitted with four rings and time of flight. The activity injected to the patients was 3.5 (±0.2) MBq/kg. The transaxial field of view (FOV) was 50 cm and the length of the axial direction was 21.6 cm, allowing covering the whole liver in one step.
The respiratory gating system consisted in an abdominal belt with a pressure sensor (AZ-733 V, Anzai Medical Co, Tokyo, Japan). The pressure signal was recorded and used for synchronized retrospective reconstructions. Six PET phases distributed equally over the breathing cycle were reconstructed for each respiratory-gated PET scan data set.
CT images were acquired by using the following parameters: pitch: 1; rotation time: 0.8 s; reconstruction: slice thickness of 2 mm and increment of 1 mm. The voltage was 120 kV and the current-time reference was 120 mAs.
The liver metastases were assessed in dimension on the different PET acquisitions with the diagnostic software from Siemens (True D) by creating Regions Of Interest (ROI) around the lesions, with an appropriate Standardized Uptake Value (SUV) threshold.
Target volume definition
For liver metastases segmentation and volume comparison, the same methodology was used between gated and non-gated PET exams in order to prevent any bias in tumor volume measurement.
Biological Target Volumes (BTV) were semi-automatically generated on the gated PET.
Normal liver Standardized Uptake Value (SUV) max was worked out for each patient within a 20 to 30 cm3 ROI inside a healthy part of the liver. To have a more reliable value, 3 ROI were used when differences of less than 0.1 in the SUVmax values were obtained. Two additional measurements were added when differences between 0.1 and 0.2 were obtained. No differences higher than 0.2 were obtained. These values were determined on the respiratory-gated phase of the PET exam identical to the respiratory phase of the CT scan of reference. This phase was chosen to avoid spatial errors in the determination of the ROI because of respiratory tumor motion. The threshold used to obtain the gated BTV was thus individualized for each patient as this normal liver Standardized Uptake Value (SUV) max. We used SUV normalized to body weight. This method was chosen to give the best differential value between tumor and normal liver (a SUV value above the SUV max of the normal liver was thus considered as part of the tumor). By applying the threshold to the six gated phases of the respiratory-gated PET exam and by adding these volumes, a Biological Internal Target Volume (BITV) was generated for each lesion of every patient. An isotropic 3 mm margin was added to account for set-up margins (patient positioning). The resulting volume was called gated Planning Target Volume (PTVg).
This 3 mm margin was chosen in accordance with the study of Hawkins et al., which demonstrated, by a kV cone-beam CT-based study, population random setup errors of 2.7 mm, 2.3 mm, and 3.0 mm respectively in the craniocaudal (CC), medio-lateral (ML) and antero-posterior (AP) directions . Another study by Dawson et al. evaluated population random setup errors to be 2.5 mm (CC), 2.8 mm (ML), and 2.9 mm (AP) . Smaller set-up errors less than 2 mm have been reported by other authors, making an isotropic 3 mm margin probably sufficient when a proper repositioning and online IGRT system is provided .
Images from the non-gated PET acquisition were used to help manual target volume definition. Furthermore, a non-gated BTV was semi-automatically created from the non-gated PET exam to help with manual target volume delineation on planning CT fused with non-gated PET, using the same method as for the respiratory-gated PET: normal liver SUV max was worked out for each patient within a 20 to 30 cm3 ROI inside a healthy part of the liver. To have a more reliable value, 3 ROI were used when differences of less than 0.1 in the SUVmax values were obtained. Two additional measurements were added when differences between 0.1 and 0.2 were obtained. No differences higher than 0.2 were obtained. The threshold used to obtain the non-gated BTV was thus individualized for each patient as this normal liver body weighted-SUV max. CT scan with contrast and/or MRI with contrast were available for target volume definition. A radiation oncologist experienced with liver SBRT treatment manually worked out the volumes, to make them more accurate, taking into account the CT scan and MRI, to better represent the real tumoral volume and excluding bones, lung and other organs-at-risk (OAR) included in the BTV. The resulting volume was called clinical target volume (CTV). An additional margin was applied to account for tumor motion and set-up margins to create a manual Planning Target Volume (PTV). A 5 mm radial and a 10 mm craniocaudal margin were chosen in accordance to the majority of the published studies on liver metastases SBRT, and considered the minimal margin to account for target volume motion and set-up margins during liver SBRT, even when active breathing control is used [6–8].
Target volumes evaluation was based on the volumes calculated by the treatment planning system. PTV and PTVg were compared for each lesion, as well as BTV with BITV. Non-parametric Wilcoxon matched pair tests were used for comparison between PTV and PTVg, and between BTV and BITV. A two-tailed p value <0.05 was used to indicate statistical significance. All analyses were made with Instat (Graphpad Software, La Jolla, CA, USA).
Segmentation assessment on phantoms
Differences between measured and real volumes varied from -42% to 137% using the Jaszczak phantom. Differences between measured and real volumes were 34% and 12% corresponding to mean measured volumes of 21.45 cm for the 16 cc sphere and 8.5 cm for the 8 cc sphere respectively, using the Torso phantom. Figure 1 shows 3-dimensional CT and PET/CT views and volume determination using the healthy liver background SUVmax segmentation method.
Maximal diameter of the lesion (cm)
SUV threshold (gated PET)
SUV threshold (non gated PET)
One interesting result is that SUV threshold was higher with the respiratory-gated exams than with the non-gated ones. Median SUV threshold in respiratory-gated exams and non-gated exams were respectively 4.45 (min: 3.9 – max: 5.0) and 3.8 (min: 3.0 – max: 5.0). The two-tailed P value was 0.0156, considered significant.
Target volumes definition
Volume characteristics and results for each lesion and every patient
Whole liver volume (cc)
Mean (+ - SD)
PTV Vs PTVg
BITV Vs BTV
SBRT for liver metastases is able to precisely target the lesions while minimizing normal tissue toxicity. Dose escalation is limited by the tolerance of the surrounding healthy liver tissue. Initial local control rates are very good at 1 year but are then limited to 57 to 92% at 2 years, depending on the studies .
PET/CT imaging with [18 F]FDG is a well-established imaging technique with clinical implications in oncology for staging, re-staging and monitoring response to therapy, including after SBRT . New software developments have highlighted its value for target volume definition and contouring purposes. However, its usefulness for radiotherapy planning has not been widely assessed and suffers from image degradation due to target movements and lack of SUV threshold standardization. As breath-holding is difficult to implement during PET/CT imaging due to the duration of the procedure, images are affected by motion artifacts and loss of contrast because of radioactivity smearing around the moving lesion, especially when the tumor is adjacent to the lungs.
Especially, cardiac and respiratory motion affects imaging because of organ displacements of up to 2 cm during normal breathing [21, 22]. Liver targets are particularly exposed to respiratory motion, making a 5 mm radial and a 10 mm craniocaudal margins probably inaccurate.
Since liver SBRT is a very precise technique in a tissue exposed to radiation toxicity, any process that aims at making radiotherapy planning more precise is of particular interest. 4D PET-CT techniques are new tools to try to compensate the motion-induced image quality degradation. It has been evaluated for lung tumors , and has proven its clinical utility for lung tumor radiotherapy planning .
In this study, we checked whether 4D PET-CT was a reliable and feasible procedure for liver radiotherapy treatment planning in order to be routinely integrated to the management of SBRT patients. The use of PET-based segmentation and volumes is often complex and it is not clear how to accurately select the threshold value for segmentation . Given the lack of standardized methods for liver segmentation, we developed a threshold-based method to segment metastases with respect to background SUVmax measured on patient healthy liver. The liver segmentation method was thus individualized in a timely and personalized fashion.
In lung cancer, 4D PET has been shown to better match tumor motion than non-gated PET images [24, 25]. Unlike for lung tumors, no standard method has been described for automatic liver tumor segmentation using PET-CT [26–28]. The volume of the BTV mostly depends on the segmentation method used and most of these methods result in unsatisfactory volumes . In head and neck tumors, it has been shown that PET-based tumor delineation yields more accurate and reproducible results with signal to background ratio than with manual/visual delineation (sensitive to window level settings and operator dependent), isocontouring based on a Standardized Uptake Value (SUV) of 2.5, or fixed percentage of the maximal SUV value (40% or 50%) delineation . The signal to background method has been validated on histology for head and neck cancer and its threshold is adapted to an individual patient . Its feasibility for liver malignancies was shown experimentally, with this method reliably estimating hepatic tumor diameter. The feasibility was also shown with physiological FDG liver uptake as the background value and a personalized threshold segmentation method based on normal liver SUVmax for tumor measurements. Although the SUVmax might not be the best value and peak and mean SUV might suffer fewer fluctuations, the SUVmax is widely-used in clinical practice for its convenience, as reported in the clinics and supported by our study. Additional studies evaluating these values for segmentation will hopefully improve our methodology and compare these methods to supposedly more reliable ones.
4D PET may have a potential for increased sensitivity compared to non-gated PET exam and contrast-enhanced CT scan as suggested by the discovery of an additional undiagnosed lesion on both modalities in one patient. Limitations of non-gated PET/CT include respiratory motion blur, poor spatial resolution and/or partial volume effect. Of clinical relevance, this lesion would have remained untreated without the use of 4D PET.
Moreover, respiratory-gated PET/CT was able to significantly decrease PTV as compared to a standard planning procedure using non-respiratory gated PET/CT. Furthermore, as BTV was significantly lower than BITV, automatic contouring based on non respiratory-gated exams may underestimate the real internal target volumes (that is the target volume accounting for respiratory motion) because of image blurring and inaccurate SUV values.
Improving SBRT treatment planning could therefore lead to a better protection of critical organs and further dose escalation, both possibly providing increased benefit-risk ratios.
Our study has a number of limitations. First of all, a potential drawback is that planning CT scan was made during non-gated acquisition, which implied matching a selected PET phase with the CT.
Furthermore, planning contrast-enhanced CT scan and planning MRI were not used in our study for radiotherapy planning [8, 9]. However, we limited this bias by integrating PET-based imaging and semi-automatic PET-based BTV directly registered with the planning CT scan of reference that didn’t require additional hazardous image co-registration or fusion [32–34]. Further investigations will be necessary to assess the role of a respiratory-gated PET in addition to contrast-enhanced CT scan as the standard planning procedure.
In comparison to non-gated PET, 4D PET may better account for the respiratory movements of liver targets and more appropriately evaluate internal target volumes. Further, reduction of irradiated liver volumes may allow for safer and potentially more efficient SBRT treatment. Finally, it might become a valuable tool to improve SBRT planning for liver metastases.
The current work was performed during the French university of diploma of innovative radiation techniques http://www.diu-radiotherapie.com.
- Dawood O, Mahadevan A, Goodman KA: Stereotactic body radiation therapy for liver metastases. Eur J Cancer 2009,45(17):2947-2959. 10.1016/j.ejca.2009.08.011View ArticlePubMedGoogle Scholar
- Lochan R, White SA, Manas DM: Liver resection for colorectal liver metastasis. Surg Oncol 2007,16(1):33-45. 10.1016/j.suronc.2007.04.010View ArticlePubMedGoogle Scholar
- Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA: Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003,10(9):1059-1069. 10.1245/ASO.2003.03.026View ArticlePubMedGoogle Scholar
- Boutros C, Espat NJ: What, how, and when to offer nonresectional therapy for colorectal cancer liver metastases. J Gastrointest Surg 2011,15(3):420-422. 10.1007/s11605-011-1428-7View ArticlePubMedGoogle Scholar
- Liang S-X, Zhu X-D, Xu Z-Y, Zhu J, Zhao J-D, Lu H-J, Yang Y-L, Chen L, Wang A-Y, Fu X-L, Jiang G-L: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006,65(2):426-434. 10.1016/j.ijrobp.2005.12.031View ArticlePubMedGoogle Scholar
- Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009,27(10):1585-1591. 10.1200/JCO.2008.20.0600View ArticlePubMedGoogle Scholar
- Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009,27(10):1572-1578. 10.1200/JCO.2008.19.6329View ArticlePubMedGoogle Scholar
- Høyer M, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA: Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012,82(3):1047-1057. 10.1016/j.ijrobp.2011.07.020View ArticlePubMedGoogle Scholar
- Pech M, Mohnike K, Wieners G, Bialek E, Dudeck O, Seidensticker M, Peters N, Wust P, Gademann G, Ricke J: Radiotherapy of liver metastases. Comparison of target volumes and dose-volume histograms employing CT- or MRI-based treatment planning. Strahlenther Onkol 2008,184(5):256-261. 10.1007/s00066-008-1849-8View ArticlePubMedGoogle Scholar
- Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brügel M, Ziegler SI, Molls M, Schwaiger M, Essler M: Respiratory gated [(18)F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol 2012,188(7):592-598. 10.1007/s00066-012-0094-3View ArticlePubMedGoogle Scholar
- Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JF, McFarland EG, Middleton WD, Balfe DM, Ritter JH: Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003,226(2):533-542. 10.1148/radiol.2262011980View ArticlePubMedGoogle Scholar
- Topal B, Flamen P, Aerts R, D’Hoore A, Filez L, Van Cutsem E, Mortelmans L, Penninckx F: Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001,27(2):175-179. 10.1053/ejso.2000.1075View ArticlePubMedGoogle Scholar
- Steffen IG, Wust P, Rühl R, Grieser C, Schnapauff D, Lüdemann L, Grabik W, Ricke J, Amthauer H, Hamm B, Lopez Hänninen E, Denecke T: Value of combined PET/CT for radiation planning in CT-guided percutaneous interstitial high-dose-rate single-fraction brachytherapy for colorectal liver metastases. Int J Radiat Oncol Biol Phys 2010,77(4):1178-1185. 10.1016/j.ijrobp.2009.06.047View ArticlePubMedGoogle Scholar
- Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL: Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 2002,43(7):876-881.PubMedGoogle Scholar
- Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB: Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys 2012,82(1):e99-e105. 10.1016/j.ijrobp.2010.12.060View ArticlePubMedGoogle Scholar
- Guerra L, Meregalli S, Zorz A, Niespolo R, De Ponti E, Elisei F, Morzenti S, Brenna S, Crespi A, Gardani G, Messa C: Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. Eur J Nucl Med Mol Imaging 2013. Nov [Epub ahead of print]Google Scholar
- Hawkins MA, Brock KK, Eccles C, Moseley D, Jaffray D, Dawson LA: Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. Int J Radiat Oncol Biol Phys 2006,66(2):610-619. 10.1016/j.ijrobp.2006.03.026View ArticlePubMedGoogle Scholar
- Dawson LA, Eccles C, Bissonnette J-P, Brock KK: Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005,62(4):1247-1252. 10.1016/j.ijrobp.2005.03.072View ArticlePubMedGoogle Scholar
- Hansen AT, Petersen JB, Høyer M: Internal movement, set-up accuracy and margins for stereotactic body radiotherapy using a stereotactic body frame. Acta Oncol 2006,45(7):948-952. 10.1080/02841860600911172View ArticlePubMedGoogle Scholar
- Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD: Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys 2012,83(5):e613-e618. 10.1016/j.ijrobp.2012.02.008View ArticlePubMedGoogle Scholar
- Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR: The management of respiratory motion in radiation oncology report of AAPM task group 76. Med Phys 2006,33(10):3874-3900. 10.1118/1.2349696View ArticlePubMedGoogle Scholar
- Brandner ED, Wu A, Chen H, Heron D, Kalnicki S, Komanduri K, Gerszten K, Burton S, Ahmed I, Shou Z: Abdominal organ motion measured using 4D CT. Int J Radiat Oncol Biol Phys 2006, 65: 554-560. 10.1016/j.ijrobp.2005.12.042View ArticlePubMedGoogle Scholar
- Nehmeh SA, El-Zeftawy H, Greco C, Schwartz J, Erdi YE, Kirov A, Schmidtlein CR, Gyau AB, Larson SM, Humm JL: An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. Med Phys 2009, 36: 4803-4809. 10.1118/1.3222732View ArticlePubMedGoogle Scholar
- Lamb JM, Robinson C, Bradley J, Laforest R, Dehdashti F, White BM, Wuenschel S, Low DA: Generating lung tumor internal target volumes from 4D-PET maximum intensity projections. Med Phys 2011,38(10):5732-5737. 10.1118/1.3633896PubMed CentralView ArticlePubMedGoogle Scholar
- Guerra L, De Ponti E, Elisei F, Bettinardi V, Landoni C, Picchio M, Gilardi MC, Versari A, Fioroni F, Dziuk M, Koza M, Ahond-Vionnet R, Collin B, Messa C: Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. Eur J Nucl Med Mol Imaging 2012,39(9):1381-1390. 10.1007/s00259-012-2148-2View ArticlePubMedGoogle Scholar
- Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, Siegel BA, Bradley JD: 18 F-FDG PET definition of gross tumor volume for radiotherapy of non–small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 2006,47(11):1808-1812.PubMedGoogle Scholar
- Black QC, Grills IS, Kestin LL, Wong C-YO, Wong JW, Martinez AA, Yan D: Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004,60(4):1272-1282. 10.1016/j.ijrobp.2004.06.254View ArticlePubMedGoogle Scholar
- Yu J, Li X, Xing L, Mu D, Fu Z, Sun X, Sun X, Yang G, Zhang B, Sun X, Ling CC: Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 2009,75(5):1468-1474. 10.1016/j.ijrobp.2009.01.019View ArticlePubMedGoogle Scholar
- Zaidi H, El Naqa I: PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging 2010,37(11):2165-2187. 10.1007/s00259-010-1423-3View ArticlePubMedGoogle Scholar
- Schinagl DAX, Vogel WV, Hoffmann AL, Van Dalen JA, Oyen WJ, Kaanders JHAM: Comparison of five segmentation tools for [(18)F]fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007,69(4):1282-1289. 10.1016/j.ijrobp.2007.07.2333View ArticlePubMedGoogle Scholar
- Daisnes JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, Grégoire V: Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR Imaging and FDG PET and validation with surgical specimen. Radiology 2004, 233: 93-100. 10.1148/radiol.2331030660View ArticleGoogle Scholar
- Scripes PG, Yaparpalvi R: Technical aspects of positron emission tomography/computed tomography in radiotherapy treatment planning. Semin Nucl Med 2012, 42: 283-288. 10.1053/j.semnuclmed.2012.04.006View ArticlePubMedGoogle Scholar
- Daisne J-F, Sibomana M, Bol A, Cosnard G, Lonneux M, Grégoire V: Evaluation of a multimodality image (CT, MRI and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol 2003, 69: 237-245. 10.1016/j.radonc.2003.10.009View ArticlePubMedGoogle Scholar
- Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, Von Schulthess GK: Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med 2002, 43: 1469-1475.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.